Condreay, Lynn D. http://orcid.org/0000-0003-0899-7979
Parham, Laura R. http://orcid.org/0000-0002-2795-9831
Qu, Xiaoyan A. http://orcid.org/0000-0001-7581-8358
Steinfeld, Jonathan http://orcid.org/0000-0002-3947-0523
Wechsler, Michael E. http://orcid.org/0000-0003-3505-2946
Raby, Benjamin A. http://orcid.org/0000-0003-2206-5748
Yancey, Steven W. http://orcid.org/0000-0002-9140-3838
Ghosh, Soumitra http://orcid.org/0000-0001-8235-4811
Funding for this research was provided by:
GlaxoSmithKline (NA)
Article History
Received: 10 September 2019
Accepted: 21 January 2020
First Online: 3 February 2020
Compliance with ethical standards
:
: L. D. Condreay, L.R. Parham, and X.A. Qu are former GlaxoSmithKline (GSK) employees and hold shares; they are currently Parexel International employees working under a GSK contract. J. Steinfeld, S.W. Yancey, and S. Ghosh are GSK employees and hold shares. M.E. Wechsler has research grants with the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute and is a consultant with GSK, Sanofi, Regeneron, Astrazeneca, Teva, Novartis, Boehringer Ingelheim. B.A. Raby has research grants with the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute and is a consultant with GSK, Regeneron, and Sanofi.